There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Rewalk Robotics (NASDAQ: RWLK) and Halozyme (NASDAQ: HALO) with bullish sentiments.
Rewalk Robotics (NASDAQ: RWLK)
In a report issued on May 11, Kyle Rose from Canaccord Genuity maintained a Buy rating on Rewalk Robotics (NASDAQ: RWLK), with a price target of $1.50. The company’s shares opened today at $1.05, equals to its 52-week low of $1.05.
Rose said:
“We maintain our BUY rating on ReWalk following Q1/18 results. ReWalk reported revenues of $1.6M, slightly above our estimate for $1.5M. System placements of 23 units was below our expectations for 28 units, but ReWalk sales were largely in line given a favorable mix of system purchases and rental conversions in the quarter. Operationally, we were encouraged by another quarter of strong demand for the ReWalk system as well as continued execution on key initiatives necessary to support long-term adoption — namely reimbursement milestones and approval of the Timwell Corporation partnership. Net, net we continue to be positive on the company’s long-term opportunity as we believe in the benefits of exoskeleton technology, ReWalk’s differentiated product, and first- mover position in space.”
According to TipRanks.com, Rose is a 5-star analyst with an average return of 11.4% and a 56.9% success rate. Rose covers the Healthcare sector, focusing on stocks such as Obalon Therapeutics Inc, Zimmer Biomet Holdings, and Smith & Nephew Snats.
Rewalk Robotics has an analyst consensus of Moderate Buy, with a price target consensus of $1.83.
See today’s analyst top recommended stocks >>
Halozyme (NASDAQ: HALO)
In a report released today, Arlinda Lee from Canaccord Genuity reiterated a Buy rating on Halozyme (NASDAQ: HALO), with a price target of $21. The company’s shares opened today at $19.87, close to its 52-week high of $21.48.
According to TipRanks.com, Lee is a 4-star analyst with an average return of 5.1% and a 47.1% success rate. Lee covers the Healthcare sector, focusing on stocks such as Karyopharm Therapeutics, Aquinox Pharmaceuticals, and Zynerba Pharmaceuticals.
Halozyme has an analyst consensus of Hold, with a price target consensus of $19.67.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
